Rubric Capital Management LP Has $45.17 Million Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Rubric Capital Management LP grew its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 10.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,419,103 shares of the company's stock after acquiring an additional 223,094 shares during the period. Rubric Capital Management LP owned 3.41% of Kiniksa Pharmaceuticals worth $45,165,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Essex Investment Management Co. LLC raised its stake in shares of Kiniksa Pharmaceuticals by 0.5% in the first quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company's stock valued at $3,408,000 after acquiring an additional 850 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Kiniksa Pharmaceuticals by 5.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company's stock valued at $413,000 after acquiring an additional 1,153 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Kiniksa Pharmaceuticals by 8.1% in the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company's stock valued at $378,000 after acquiring an additional 1,435 shares during the last quarter. Linden Thomas Advisory Services LLC raised its stake in shares of Kiniksa Pharmaceuticals by 1.7% in the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company's stock valued at $2,209,000 after acquiring an additional 1,921 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Kiniksa Pharmaceuticals by 7.8% in the first quarter. Janney Montgomery Scott LLC now owns 26,843 shares of the company's stock valued at $530,000 after acquiring an additional 1,940 shares during the last quarter. Institutional investors own 53.95% of the company's stock.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the sale, the insider now owns 52,038 shares of the company's stock, valued at approximately $1,359,232.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, COO Eben Tessari sold 17,500 shares of the business's stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total value of $470,925.00. Following the completion of the transaction, the chief operating officer now owns 119,911 shares of the company's stock, valued at approximately $3,226,805.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Paolini sold 60,692 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the completion of the transaction, the insider now directly owns 52,038 shares of the company's stock, valued at approximately $1,359,232.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 260,564 shares of company stock valued at $6,727,929. Company insiders own 54.57% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on KNSA shares. Jefferies Financial Group started coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They issued a "buy" rating and a $40.00 target price for the company. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an "outperform" rating in a report on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $33.60.

Kiniksa Pharmaceuticals Trading Down 2.3 %

Shares of Kiniksa Pharmaceuticals stock traded down $0.61 during midday trading on Friday, reaching $25.64. The company had a trading volume of 3,247,992 shares, compared to its average volume of 426,628. The stock has a fifty day simple moving average of $25.20 and a 200 day simple moving average of $21.24. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $14.12 and a 1-year high of $27.92. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 233.09 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The firm had revenue of $108.30 million during the quarter, compared to analyst estimates of $90.60 million. During the same quarter in the previous year, the business earned ($0.02) EPS. The business's quarterly revenue was up 51.5% compared to the same quarter last year. Sell-side analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.31 earnings per share for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.